Role of High-sensitivity C-reactive Protein in Future Cardiovascular Events in Hemodialysis Patients
In Vivo · 2024
DOI: 10.21873/invivo.13575 ↗Kurz gefasst
Fachartikel in der Zeitschrift In Vivo, 2024. Verfasst von Hiroshi Osawa und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Medicine, Hirosaki University Hospital, Hirosaki, Japan; osawa@hirosaki-u.ac.jp. Hauptthemen laut MEDLINE: C-Reactive Protein, Renal Dialysis, Cardiovascular Diseases, Biomarkers. Die Arbeit wurde bisher 10-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
BACKGROUND/AIM: The pathogenesis of cardio-vascular disease (CVD) in hemodialysis (HD) patients involves inflammation and oxidative stress. High-sensitivity C-reactive protein (hs-CRP) is an established inflammatory biomarker associated with CVD. Several studies have suggested that the inflammatory biomarker pentraxin-3 (PTX-3) and the oxidative stress-related biomarker soluble lectin-like low-density lipoprotein receptor-1 (sLOX-1) are novel biomarkers for CVD in non-HD populations. This study aimed to clarify the association of these established and novel biomarkers with future cardiovascular (CV) events in HD patients. PATIENTS AND METHODS: This was a single-center prospective cohort study that included 255 HD patients. The primary outcome was the composite of nonfatal and fatal CV events. The event-free survival rate between the two groups according to the median plasma level of each biomarker at baseline was evaluated using the Kaplan-Meier method. The risk for CV events at elevated levels of each biomarker was estimated using Cox proportional hazard model. RESULTS: We observed 44 CV events during the median follow-up period of 743 days. The event-free survival rate significantly differed between the two groups in hs-CRP but not in PTX-3 or sLOX-1. The unadjusted hazard ratio (HR) for CV events in patients with hs-CRP levels above the median was 2.63 [95% confidence interval (CI)=1.37-5.02]. The HR remained significant after adjusting for age, sex, history of CVD, and diabetes (HR=2.30; 95%CI=1.20-4.43). CONCLUSION: In HD patients, hs-CRP may have a predictable role for future CV events, whereas PTX-3 and sLOX-1 do not.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of General Medicine, Hirosaki University Hospital, Hirosaki, Japan; osawa@hirosaki-u.ac.jp.
- Department of Nursing Science, Hirosaki University Graduate School of Health Science, Hirosaki, Japan.
- Oyokyo Kidney Research Institute, Hirosaki Hospital, Hirosaki, Japan.
- Department of Cardiology and Nephrology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.
- Department of Advanced Transplant and Regenerative Medicine, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.
- Department of Emergency and Disaster Medicine, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.
Zitieren
APA
Osawa, H., Nakamura, N., Tsutaya, C., Saitoh, H., Shimada, M., Murakami, R., Fujita, T., Narita-Kinjo, I., Nagawa, D., Nakata, M., Yokota, T., Ohyama, C., & Tomita, H. (2024). Role of High-sensitivity C-reactive Protein in Future Cardiovascular Events in Hemodialysis Patients. In Vivo. https://doi.org/10.21873/invivo.13575
Vancouver
Osawa H, Nakamura N, Tsutaya C, Saitoh H, Shimada M, Murakami R, et al. Role of High-sensitivity C-reactive Protein in Future Cardiovascular Events in Hemodialysis Patients. In Vivo. 2024. doi:10.21873/invivo.13575
BibTeX
@article{Osawa2024,
author = {Osawa, Hiroshi and Nakamura, Norio and Tsutaya, Chikako and Saitoh, Hisao and Shimada, Michiko and Murakami, Reiichi and Fujita, Takeshi and Narita-Kinjo, Ikuyo and Nagawa, Daiki and Nakata, Masamichi and Yokota, Takashi and Ohyama, Chikara and Tomita, Hirofumi},
title = {Role of High-sensitivity C-reactive Protein in Future Cardiovascular Events in Hemodialysis Patients},
journal = {In Vivo},
year = {2024},
doi = {10.21873/invivo.13575}
}
EUVIMED